Biomarker research in Parkinsons disease: Objective measures needed for patient stratification in future cause-directed trials

Biomarkers in Medicine

Volumn 4, Issue 5, 2010, Pages 647-650

  Schlossmacher, Michael G ^b   Mollenhauer, Brit ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; PARKIN; BRCA1 PROTEIN; LRRK2 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE; PTEN-INDUCED PUTATIVE KINASE; SYNUCLEIN;

CEREBROSPINAL FLUID; CLINICAL RESEARCH; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; EDITORIAL; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HUMAN; MEDICAL RESEARCH; NERVOUS TISSUE; NONHUMAN; PARKINSON DISEASE; STRATIFIED SAMPLE; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM;

BIOLOGICAL MARKERS; BRCA1 PROTEIN; CLINICAL TRIALS AS TOPIC; HUMANS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SYNUCLEINS;

EID: 77958023741     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.93     Document Type: Editorial

References (17)

1. Klein C, Schlossmacher MG: Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69(22), 2093-2104 (2007).
2. Trojanowski JQ, Growdon JH: A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. J. Neuropathol. Exp. Neurol. 57(6), 643-644 (1998).
3. Stiasny-Kolster K, Doerr Y, Moller JC et al.: Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for a-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128(Pt 1), 126-137 (2005).
4. Frasier M, Chowdhury S, Eberling J, Sherer T: Biomarkers in Parkinson's disease: a funder's perspective. Biomarkers Med. 4(5), 723-729 (2010).
5. Eckstein JW: Biomarkers in Parkinson's disease: a venture capitalist's perspective. Biomarkers Med. 4(5), 731-735 (2010).
6. Brooks DJ: Imaging dopamine transporters in Parkinson's disease. Biomarkers Med. 4(5), 651-660 (2010).
7. Morley JF, Duda JE: Olfaction as a biomarker in Parkinson's disease. Biomarkers Med. 4(5), 661-670 (2010).
8. Nyhlén J, Constantinescu R, Zetterberg H: Problems associated with fluid biomarkers for Parkinson's disease. Biomarkers Med. 4(5), 671-681 (2010).
9. Mollenhauer B, El-Agnaf OMA, Katrin M, Trenkwalder C, Schlossmacher MG: Quantification of a-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers Med. 4(5), 683-699 (2010).
10. Cipriani S, Chen X, Schwarzschild MA: Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers Med. 4(5), 701-712 (2010).
11. Lopez G, Sidransky E: Autosomal recessive mutations in the development of Parkinson's disease. Biomarkers Med. 4(5), 713-721 (2010).
12. Wiltfang J, Lewczuk P, Riederer P et al.: Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry 6(2), 69-84 (2005).
13. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord. 16(4), 622-630 (2001).
14. Berg D: Transcranial ultrasound as a risk marker for Parkinson's disease. Mov. Disord. 24(Suppl. 2), S677-S683 (2009).
15. Bogdanov M, Matson WR, Wang L et al.: Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131(2), 389-396 (2008).
16. Hennecke G, Scherzer CR: RNA biomarkers of Parkinson's disease: developing tool for new therapies. Biomarkers Med. 2(1), 41-53 (2008).
17. Gasser T: Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog. Brain Res. 183, 3-20 (2009).